VacLogic+ Maintenance Release 1.3.8 | All Practices: November 21, 2023

Forecasting Revisions

Based on FDA / CDC guidelines, this version of VacLogic+ forecasting has been revised to accurately reflect the following recommendations:

Updated Vaccine Forecasting to Include PCV20 in the Following Routine and Catch-up Schedules:

• Routine use: Children ages 2-23 months should get either PCV15 or PCV20 according to recommended dosing and schedules. This would be the 4-dose series at 2, 4, 6, and 12-15 months either in its entirety, or a mid-series transition to PCV20
• Catch-up vaccination: Healthy children ages 24-59 months with incomplete PCV vaccination status receive either PCV15 or PCV20 according to currently recommended dosing and schedules

Corrected a Pop-up Warning When a Previously Administered Vaccine Status Changed to Invalid

Users will no longer see the pop-up warning stating "COVID PRF 2023-24 is OK to give, but [COVID-19, mRNA, 6mos-4yrs, Pfizer] invalid; consider non-combination vaccines. (status = partial) Continue anyway?"

Note that a release to address the high-risk pneumococcal series forecasting as well as revising the indicator status within a patient’s chart to reflect the two different high risk pathways (1 or 2 doses) is in progress and will be made available as soon as testing has been completed.

VacLogic+ Maintenance Release 1.3.7 | All Practices: October 19, 2023

Issue Resolutions

Fall 2023 COVID VL+ Vaccine Logic Revisions

After releasing the CDC's updated fall 2023 COVID vaccination guidelines / forecasting, we discovered and corrected issues related to:

• Flagging a previously valid dose of a child's primary series invalid after the fall 2023 dose was administered. Now, none of the previous valid primary series doses will be inappropriately flagged as invalid.
• An inappropriate warning about giving an appropriate dose of 6m-11 Moderna product to a child who is 11 years old. Now, the warning does not appear unless the patient is truly outside of the recommended age band.

VacLogic+ Maintenance Release 1.3.6 | All Practices: October 3, 2023

VacLogic+ Enhancements

Fall 2023 Monovalent Formulations of COVID19 Vaccines Forecasting

Based on the most recent FDA / CDC guidelines regarding the authorization of the fall 2023 monovalent formulations of COVID19 vaccines, and removing authorization for the use of any prior bivalent vaccines, this version of VacLogic+ forecasting has been revised to accurately reflect the following recommendations specific to the COVID vaccine in children:

• Individuals 5 years of age and older regardless of previous vaccination are eligible to receive a single dose of an updated mRNA COVID-19 vaccine at least 2 months since the last dose of any COVID-19 vaccine
• Individuals 6 months through 4 years of age who have previously been vaccinated against COVID-19 are eligible to receive one or two doses of an updated mRNA COVID-19 vaccine (timing and number of doses to administer depends on the previous COVID-19 vaccine received)
• Unvaccinated individuals 6 months through 4 years of age are eligible to receive three doses of the updated authorized Pfizer-BioNTech COVID-19 Vaccine or two doses of the updated authorized Moderna COVID-19 Vaccine

Warning When COVID Vaccine Administered Outside of Age Group

Additionally, this version adds support for a pop-up warning if a user attempts to order an age-specific COVID vaccine to a patient that is either younger or older than that recommended age range.

Note: This functioning is not applicable to the vaccines listed below, as even though they reflect different age ranges, they all share the same CVX code:

• COVID19 MOD BIV
• COVID19 MOD BIV 6-11
• COVID19 MOD BIV 6m-11

VacLogic+ Maintenance Release 1.3.5 | All Practices: September 7, 2023

Issue Resolutions

Based on the most recent FDA / CDC guidelines regarding removing authorization for the use of any monovalent COVID 19 vaccines and moving to only the current bivalent strains being used for all doses in the vaccine schedule, in this version of VacLogic+, forecasting has been corrected to accurately reflect the following recommendations specific to the Covid bivalent booster in children:

Moderna - Individuals 6 months through 5 years of age:

• Unvaccinated individuals:  Two doses of Moderna COVID-19 Vaccine, Bivalent are administered. The second dose is administered 4 weeks after the first.
• Individuals who have received one dose of Moderna COVID-19 Vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered 4 weeks after the dose of Moderna COVID-19 Vaccine.
• Individuals who have received two doses of Moderna COVID-19 Vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered at least 8 weeks after the last dose of Moderna COVID-19 Vaccine.
• For immunocompromised individuals 6 months through 5 years of age who have received two doses (Moderna COVID-19 Vaccine or Moderna COVID-19 Vaccine, Bivalent): A single additional dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 8 weeks following the most recent dose of Moderna COVID-19 Vaccine, Bivalent; additional doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances.

Moderna - Individuals 6 years of age and older:

• Unvaccinated individuals: A single dose of Moderna COVID-19 Vaccine, Bivalent.
• Individuals who have received one or more doses of a monovalent COVID-19 vaccine: A single dose of Moderna COVID-19 Vaccine, Bivalent is administered at least 8 weeks after any monovalent COVID-19 vaccine.
• For immunocompromised individuals 6 years of age and older: A single additional age-appropriate dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 8 weeks following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstance

Pfizer - Individuals 6 months through 4 years of age:

• Unvaccinated individuals: Three doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent are administered over at least 11 weeks. The first two doses are administered 3 weeks apart. The third dose is administered at least 8 weeks after the second dose.
• Individuals who have received one dose of the monovalent Pfizer BioNTech COVID-19 Vaccine: Two doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent are administered. The first dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent is given 3 weeks after the monovalent Pfizer-BioNTech COVID-19 Vaccine and the second dose at least 8 weeks later.
• Individuals who have received two doses of the monovalent Pfizer BioNTech COVID-19 Vaccine: A single dose of Pfizer-BioNTech COVID 19 Vaccine, Bivalent is administered at least 8 weeks after the monovalent Pfizer-BioNTech COVID-19 Vaccine.
• Individuals who have received three doses of the monovalent Pfizer BioNTech COVID-19 Vaccine: A single dose of Pfizer-BioNTech COVID 19 Vaccine, Bivalent is administered at least 8 weeks after the monovalent Pfizer BioNTech COVID-19 Vaccine.
• Immunocompromised individuals 6 months through 4 years of age who have received three doses (Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent): A fourth dose with Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 8 weeks following the most recent dose; additional doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider

Pfizer - Individuals 5 years of age and older:

• Unvaccinated individuals: A single dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent. 
• Individuals who have received one or more doses of a monovalent COVID 19 vaccine: A single dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent is administered at least 8 weeks after any monovalent COVID-19 vaccine.
• Immunocompromised individuals 5 years of age and older who have received one dose of a bivalent COVID-19 vaccine: An additional dose with Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 8 weeks following the dose of the bivalent COVID-19 vaccine; additional doses may be administered at the discretion of the healthcare provider.

VacLogic+ Maintenance Release 1.3.4 | All Practices: May 2, 2023

Issue Resolutions

Covid Bivalent Booster Forecasting in Children Corrected

In this version of VacLogic+, forecasting has been corrected to accurately reflect the following situations specific to the Covid bivalent booster forecasting in children:

• If a child is between 6m and 4 years old AND they have completed a valid 3 dose primary series of the MONOVALENT Pfizer 6m-4yr vaccine AND the last dose was at least 2 months ago, then they will be forecasted as DUE, as they will be eligible for a bivalent booster dose.
• OP is aware of the recently released CDC recommendations regarding monovalent Covid vaccines no longer being authorized and changes in the schedule related to bivalent vaccines. We are actively working on modifications to this forecasting for a subsequent release.

VacLogic+ Maintenance Release 1.3.3 | All Practices: March 20, 2023

Issue Resolutions

Covid Bivalent Booster Forecasting in Children Corrected

In this version of VacLogic+, forecasting has been corrected to accurately reflect the following situations specific to the Covid bivalent booster forecasting in children:

• If a child is between 6m and 4 years old, and they have received 3 valid doses of Pfizer 6m-4 year monovalent OR 2 doses of monovalent and 1 dose of bivalent, then they will be forecasted as SC (series complete). This forecasting will remain SC until the child reaches age 5 AND it is at least 2 months since their most recent dose.
• If a child is 5 years or older and they have received either 3 valid doses of Pfizer 6m-4 monovalent OR 2 valid doses of Moderna 6m-5 monovalent, AND it is at least 2 months since the most recent dose, then they will be forecasted as DUE, as they are now eligible for a bivalent booster dose.

Rotavirus “View Plan History” Section Text Updated

In the View Plan History section for rotavirus, the text has been changed to say “Rotavirus series considered complete after 8 months of age”. Previously, the text read “8 years of age”.

Zoster Vaccine Group Display Corrected

OP corrected an issue where Zoster vaccines were not displayed in the Immunization forecast. Zoster vaccines will now appear in the Miscellaneous section.